Objective To study the clinical effects of Tacrolimus ointment combined with recombinant human epidermal growth factor gel in treating hormone dependent facial dermatitis , so as to obtain scientific knowledge for clinical practice . Method 47 patients suffering hormone dependent facial dermatitis admitted to Quhua Hospital were randomly divided into an experimental group of 24 cases and a control group 23 cases.The experimental group were treated with a combination of Tacrolimus ointment and recombinant human epidermal growth factor gel , while the control group were treated with Tacrolimus ointment only .After one month of treatment , the clinical effects of the medicines on both groups , the recurrence rate and the adverse reaction in both groups were examined and compared .Findings Erythema, desquamation, papules,pustules, pigmentation of the symptoms and signs of integral of the two groups of patients after treatment were found to besignificantly lower than before treatment (P <0.05 ); The total efficiency of two groups were no statistical significance (P >0.05 ), but the recurrence rate of the experimental group (16.67%) was significantly lower than that of the controlgroup ( 52.17% =7.823, P <0.05 ); the incidence rate of adverse reaction in the two groups of patients had nosignificant difference (-x ±s =0.636, P >0.05), and no serious adverse reaction was observed .Conclusion TacrolimusOintment combined with recombinant human growth factor gel can serve as an effective medicine in treating hormonedependent dermatitis, where the recurrence rate is low and safety is high .%目的：探讨他克莫司软膏与重组人表皮生长因子凝胶联合治疗面部激素依赖性皮炎的临床疗效，为临床治疗方案的制定提供参考。方法选取我院皮肤科收治的47例面部激素依赖性皮炎的患者，随机数字表法将其分为观察组24例和对照组23例，分别采用他克莫司软膏与重组人表皮生长因子凝胶联合治疗和单纯应用他克莫司软膏治疗。治疗1个月后，对比两组患者的临床疗效、复发率以及不良反应发生情况。结果两组患者治疗后红斑、脱屑、丘疹、脓疱、色素沉着的症状和体征积分均显著低于治疗前（均P＜0．05）；两组总有效率差异没有统计学意义（P＞0．05），但观察组复发率（16．67％）显著低于对照组的52．17％（χ2＝7．823，P＜0．05）；两组患者不良反应的发生率差异无统计学意义（χ2＝0．636，P＞0．05）。结论他克莫司软膏联合重组人生长因子凝胶治疗面部激素依赖性皮炎具有良好的临床疗效，且复发率较低，安全性高，值得在临床上进一步推广应用。
展开▼
